PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ
Market Cap
$85.4M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
709 of 809
Rank in Industry
384 of 445
Largest Insider Buys in Sector
PMVP Stock Price History Chart
PMVP Stock Performance
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Insider Activity of PMV Pharmaceuticals, Inc.
Over the last 12 months, insiders at PMV Pharmaceuticals, Inc. have bought $0 and sold $264,578 worth of PMV Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at PMV Pharmaceuticals, Inc. have bought $106.6M and sold $24.75M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,900,000 shares for transaction amount of $34.2M was made by RA CAPITAL MANAGEMENT, L.P. (10 percent owner) on 2020‑09‑29.
List of Insider Buy and Sell Transactions, PMV Pharmaceuticals, Inc.
| 2023-11-22 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 87,786 0.1816% | $2.23 | $195,763 | -19.19% | |
| 2023-09-15 | Sale | Alland Leila | Chief Medical Officer | 6,291 0.0128% | $6.62 | $41,646 | -72.24% | |
| 2023-09-15 | Sale | Jalota Deepika | Chief Development Officer | 4,104 0.0084% | $6.62 | $27,168 | -72.24% | |
| 2022-05-26 | Sale | OrbiMed Genesis GP LLC | 26,253 0.0695% | $15.93 | $418,210 | -25.36% | ||
| 2022-03-29 | Sale | ORBIMED CAPITAL LLC | 365,000 0.7867% | $21.52 | $7.85M | -45.86% | ||
| 2021-10-06 | Sale | Schroeder Thilo | director | 800 0.0019% | $30.15 | $24,120 | -43.26% | |
| 2021-10-04 | Sale | Schroeder Thilo | director | 100 0.0002% | $30.08 | $3,008 | -43.75% | |
| 2021-10-01 | Sale | Schroeder Thilo | director | 11,541 0.0255% | $30.10 | $347,384 | -46.13% | |
| 2021-09-30 | Sale | Schroeder Thilo | director | 2,978 0.0066% | $30.03 | $89,429 | -45.30% | |
| 2021-09-29 | Sale | Schroeder Thilo | director | 5,708 0.0127% | $30.04 | $171,468 | -45.33% | |
| 2021-09-27 | Sale | Schroeder Thilo | director | 1,753 0.004% | $30.11 | $52,783 | -44.51% | |
| 2021-09-22 | Sale | Schroeder Thilo | director | 100 0.0002% | $30.00 | $3,000 | -41.71% | |
| 2021-09-22 | Sale | LEVINE ARNOLD J | director | 3,500 0.0082% | $30.00 | $105,000 | -41.71% | |
| 2021-09-17 | Sale | Schroeder Thilo | director | 711 0.0016% | $30.03 | $21,351 | -42.79% | |
| 2021-09-13 | Sale | Schroeder Thilo | director | 13,272 0.0311% | $30.20 | $400,814 | -40.29% | |
| 2021-09-10 | Sale | Schroeder Thilo | director | 43,227 0.0948% | $30.51 | $1.32M | -44.58% | |
| 2021-09-09 | Sale | Schroeder Thilo | director | 14,329 0.0332% | $30.31 | $434,312 | -40.96% | |
| 2021-09-09 | Sale | Alland Leila | Chief Medical Officer | 100 0.0002% | $30.25 | $3,025 | -40.96% | |
| 2021-09-07 | Sale | Alland Leila | Chief Medical Officer | 3,900 0.009% | $30.25 | $117,975 | -40.85% | |
| 2021-09-02 | Sale | Schroeder Thilo | director | 5,400 0.0123% | $30.15 | $162,810 | -41.70% |
Insider Historical Profitability
<0.0001%
| Alland Leila | Chief Medical Officer | 45909 0.0897% | $1.66 | 0 | 8 | |
| Jalota Deepika | Chief Development Officer | 29946 0.0585% | $1.66 | 0 | 2 | |
| ORBIMED ADVISORS LLC | 10 percent owner | 0 0% | $1.66 | 1 | 1 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 1710265 3.3431% | $1.66 | 1 | 0 | <0.0001% |
| Schroeder Thilo | director | 1101283 2.1527% | $1.66 | 0 | 62 | |
| Boxer Capital, LLC | 950000 1.857% | $1.66 | 1 | 0 | <0.0001% | |
| Thompson Peter A. | 475000 0.9285% | $1.66 | 1 | 0 | <0.0001% | |
| LEVINE ARNOLD J | director | 409842 0.8011% | $1.66 | 0 | 5 | |
| Euclidean Capital LLC | director | 127099 0.2484% | $1.66 | 0 | 6 | |
| ORBIMED CAPITAL LLC | 109500 0.214% | $1.66 | 0 | 1 | ||
| OrbiMed Genesis GP LLC | 87786 0.1716% | $1.66 | 0 | 1 | ||
| ORONSKY ARNOLD L | 55555 0.1086% | $1.66 | 1 | 0 | <0.0001% | |
| INTERWEST PARTNERS X LP | director | 55555 0.1086% | $1.66 | 1 | 0 | <0.0001% |
| Mack David Henry | President and CEO | 12470 0.0244% | $1.66 | 0 | 5 | |
| Kung Winston | COO, CFO | 1600 0.0031% | $1.66 | 0 | 4 | |
| Heyman Richard A. | director | 0 0% | $1.66 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| OrbiMed | $11.01M | 12.59 | 6.48M | 0% | +$0 | 0.23 | |
| Arrowmark Colorado Holdings Llc | $5.44M | 6.22 | 3.2M | +17.86% | +$823,842.07 | 0.01 | |
| BlackRock | $5.29M | 6.05 | 3.11M | -3.7% | -$203,129.59 | <0.0001 | |
| Euclidean Capital Llc | $4.47M | 5.11 | 2.63M | 0% | +$0 | 0.58 | |
| The Vanguard Group | $4.17M | 4.77 | 2.45M | +1.95% | +$79,566.81 | <0.0001 | |
| Alkeon Capital Management Llc | $3.99M | 4.56 | 2.35M | 0% | +$0 | 0.02 | |
| Acadian Asset Management | $3.53M | 4.04 | 2.08M | +170.7% | +$2.23M | 0.01 | |
| Citadel Advisors LLC | $2.69M | 3.07 | 1.58M | +28.46% | +$595,340.00 | <0.01 | |
| Bank of America | $2.33M | 2.66 | 1.37M | -5% | -$122,274.17 | <0.0001 | |
| Bml Capital Management Llc | $2.22M | 2.54 | 1.31M | New | +$2.22M | 1.69 | |
| PFM Health Sciences | $2.17M | 2.48 | 1.28M | -13.41% | -$335,836.64 | 0.06 | |
| Goldman Sachs | $1.86M | 2.13 | 1.1M | +36.42% | +$497,037.50 | <0.0001 | |
| Geode Capital Management | $1.54M | 1.76 | 903,137 | +4.97% | +$72,769.52 | <0.0001 | |
| Jacobs Levy Equity Management | $1.41M | 1.61 | 826,704 | +92.42% | +$675,005.50 | 0.01 | |
| State Street | $1.34M | 1.53 | 785,990 | +8.64% | +$106,311.20 | <0.0001 | |
| D. E. Shaw & Co. | $1.23M | 1.4 | 720,635 | +189.99% | +$802,620.67 | <0.01 | |
| GHOST TREE CAPITAL LLC | $1.15M | 1.31 | 675,000 | -6.9% | -$85,000.00 | 0.37 | |
| Millennium Management LLC | $1.11M | 1.27 | 655,461 | New | +$1.11M | <0.01 | |
| Ecor1 Capital Llc | $963,694.00 | 1.1 | 566,879 | 0% | +$0 | 0.03 | |
| Personal Cfo Solutions Llc | $935,581.00 | 1.07 | 550,342 | 0% | +$0 | 0.15 | |
| Citigroup | $888,629.00 | 1.02 | 522,723 | +0.41% | +$3,597.20 | <0.01 | |
| Barclays | $839,000.00 | 0.96 | 493,550 | -4.6% | -$40,482.11 | <0.0001 | |
| Opaleye Management Inc | $802,130.00 | 0.92 | 471,481 | New | +$802,130.00 | 0.13 | |
| Connor Clark & Lunn Investment Management Ltd | $737,550.00 | 0.84 | 433,853 | +134.36% | +$422,840.94 | <0.01 | |
| Morgan Stanley | $717,109.00 | 0.82 | 421,828 | +5.67% | +$38,505.07 | <0.0001 | |
| Two Sigma | $679,507.00 | 0.78 | 399,710 | +43.42% | +$205,715.30 | <0.01 | |
| Two Sigma Advisers LP | $621,180.00 | 0.71 | 365,400 | +93.74% | +$300,560.00 | <0.01 | |
| Acuitas Investments, LLC | $598,188.00 | 0.68 | 351,875 | New | +$598,188.00 | 0.31 | |
| Northern Trust | $574,828.00 | 0.66 | 338,134 | +3.33% | +$18,547.01 | <0.0001 | |
| Baker Bros Advisors LP | $547,441.00 | 0.63 | 322,024 | 0% | +$0 | 0.01 | |
| Dimensional Fund Advisors | $463,861.00 | 0.53 | 272,859 | -51.05% | -$483,841.13 | <0.0001 | |
| Charles Schwab | $452,071.00 | 0.52 | 265,924 | +2.86% | +$12,574.91 | <0.0001 | |
| M&T Bank | $439,711.00 | 0.5 | 258,484 | +30.76% | +$103,431.19 | <0.01 | |
| Point72 Asset Management | $349,954.00 | 0.4 | 205,855 | -72.56% | -$925,307.92 | <0.01 | |
| Verition Fund Management Llc | $341,595.00 | 0.39 | 200,938 | -87.29% | -$2.35M | <0.01 | |
| Shay Capital Llc | $335,203.00 | 0.38 | 197,178 | New | +$335,203.00 | 0.1 | |
| Xtx Topco Ltd | $331,510.00 | 0.38 | 195,006 | -21.81% | -$92,490.14 | 0.02 | |
| Nuveen | $260,031.00 | 0.3 | 152,959 | 0% | +$0 | <0.0001 | |
| Susquehanna International Group | $259,065.00 | 0.3 | 152,391 | +630.75% | +$223,613.16 | <0.0001 | |
| Schonfeld Group | $241,039.00 | 0.28 | 141,788 | 0% | +$0 | <0.01 | |
| UBS | $227,161.00 | 0.26 | 133,624 | +4.5% | +$9,785.21 | <0.0001 | |
| Marshall Wace | $224,137.00 | 0.26 | 131,845 | New | +$224,137.00 | <0.0001 | |
| JPMorgan Chase | $202,757.00 | 0.23 | 119,269 | -96.97% | -$6.48M | <0.0001 | |
| BNY Mellon | $199,072.00 | 0.23 | 117,101 | -6.68% | -$14,256.22 | <0.0001 | |
| AQR Capital | $195,458.00 | 0.22 | 114,975 | -27.07% | -$72,539.19 | <0.0001 | |
| Man Group Plc | $194,534.00 | 0.22 | 114,432 | New | +$194,534.00 | <0.0001 | |
| Fishman Jay A Ltd Mi | $136,000.00 | 0.16 | 80,000 | +166.67% | +$85,000.00 | 0.02 | |
| Bridgeway Capital Management | $127,500.00 | 0.15 | 75,000 | -61.52% | -$203,830.00 | <0.01 | |
| Assenagon Asset Management S.A. | $120,384.00 | 0.14 | 70,814 | 0% | +$0 | <0.0001 | |
| Tealwood Asset Management | $108,816.00 | 0.12 | 64,009 | New | +$108,816.00 | 0.02 |